Moderna, Inc. (MRNA) Stock Overview
Explore Moderna, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Moderna, Inc. (MRNA)
Key Financials
Key Financials
Market Cap
63B
P/E Ratio
-19.86
EPS (TTM)
$-8.15
ROE
-0.39%
MRNA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Moderna, Inc. (NASDAQ: MRNA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Moderna, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of MRNA on the NASDAQ shows an RSI of 72.57, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $62.86 for the NASDAQ listing.
Key metrics behind Moderna, Inc.'s NASDAQ-traded stock include a P/E ratio of -19.86 and a market capitalization of 63B. Combined with our AI analysis, these give both institutional and retail investors a clear view of MRNA on the NASDAQ.